Is Johnson & Johnson a Buy After Its Latest Earnings Report?
2026-07-16 03:19
•Eric Volkman •The Motley Fool
••• • Axe Capital view
J&J’s Mixed Quarter: A Cautious Nod from Across the Pond
Johnson & Johnson beat earnings but still fell short of investor expectations, leaving a cautious aftertaste.
Johnson & Johnson’s latest report is a textbook case of ‘barbell’ performance. Strong growth in oncology and immunology drugs like Darzalex and Tremfya propels future outlooks, but underwhelming sales in the Abiomed heart pump segment cast a shadow. The 2% drop in Abiomed, partly due to a UK study questioning its device, rattled confidence even though the broader pharma side held up well. For South African investors, the direct play isn’t obvious—JNJ’s link to the JSE and rand is thin. But weaker US health stocks often weigh on the USD/ZAR, especially if risk sentiment gets fragile. The rand could wobble if jitters over global healthcare stocks persist, though the recent rand recovery means this isn’t a guarantee. I’d say J&J is worth watching, not chasing right now. If you’re keen on global pharma exposure, look for a better entry point. This view might prove wrong if Abiomed rebounds or J&J unveils breakthrough drug developments. this is just my opinion and not financial advice
Hold off buying J&J for now and watch for clearer signs of stabilizing device sales. Use any rand strength to add selectively to South African defensive stocks instead.
- JNJ
- USD/ZAR
- Naspers
- Abiomed device segment declines more than expected
- Rand weakens sharply on global risk-off moves
5/10
Johnson & Johnson reported Q2 earnings that beat analyst estimates but disappointed investors, causing a 3% stock decline. While the company raised 2026 guidance and showed strong performance in key drugs like Darzalex and Tremfya, growth was modest compared to competitors. A concerning 2% decline in Abiomed heart pump sales, potentially linked to a negative UK study, raised concerns about the medical device segment.
This article was originally published by The Motley Fool and has been adapted here for Axe Capital Trading News.
Publisher: The Motley Fool
Author: Eric Volkman
Categories: Equities, Earnings, Healthcare
Tickers: JNJ
Sentiment: Neutral - Mixed results: company beat earnings estimates and raised 2026 guidance, showing strong growth in oncology and immunology drugs. However, investor reaction was negative (3% decline) due to modest beats relative to expectations and concerning weakness in the Abiomed device line. The author views it as a 'bargain buy' but acknowledges it wasn't a 'blowout' quarter and competitors may be delivering more impressive growth.
Keywords: earnings report, pharmaceutical, medical devices, drug sales, guidance raise, Darzalex, Tremfya, Abiomed
Insights:
- JNJ: Neutral: Mixed results: company beat earnings estimates and raised 2026 guidance, showing strong growth in oncology and immunology drugs. However, investor reaction was negative (3% decline) due to modest beats relative to expectations and concerning weakness in the Abiomed device line. The author views it as a 'bargain buy' but acknowledges it wasn't a 'blowout' quarter and competitors may be delivering more impressive growth.